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Background  and  purpose     After  joint  replacement,  a  repair 
process starts at the interface between bone and cement. If this 
process  is  disturbed,  the  prosthesis  may  never  become  rigidly 
fixed to the bone, leading to migration—and with time, loosening. 
Cox-2 inhibitors are widely used as postoperative analgesics, and 
have adverse effects on bone healing. This could tamper prosthe-
sis fixation. We investigated whether celecoxib, a selective Cox-2 
inhibitor, increases prosthesis migration in total knee replacement 
(TKR).
Methods   50 patients were randomized to either placebo or 
celecoxib treatment, 200 mg twice daily, for 3 weeks after TKR 
(NexGen; Zimmer). Maximum total point motion (MTPM) of the 
tibial component was measured after 2 years using radiostereo-
metric analysis (RSA). In addition, range of motion, pain, and, 
subjective outcome were evaluated.
Results   No differences in prosthesis migration, pain scores, 
range of motion, and subjective outcome were found after 2 years. 
Confidence intervals were narrow. 
Interpretation   It is unlikely that Celecoxib increases the risk of 
loosening, and it may be used safely in conjunction with TKR.

Cyclooxygenase-2 (Cox-2) is involved in the bone healing 
process and is inhibited by both selective and non-selective 
inhibitors. There is strong evidence from animal studies that 
Cox-2 inhibitors delay bone healing in diaphyseal fracture 
models (Zhang et al. 2002, Seidenberg and An 2004, Gersten-
feld et al. 2007, Saudan et al. 2007), and small effects have 
also been found in a stable fixation model in metaphyseal 
bone in rats (Meunier and Aspenberg 2006). In humans, there 
is strong evidence that Cox inhibitors inhibit heterotopic bone 
formation (Wahlstrom et al. 1991, Saudan, et al. 2007) and 
they also appear to delay bone healing in diaphyseal fractures 
(Giannoudis et al. 2000, Burd et al. 2003) and spinal fusion 
(Reuben et al. 2005). Even so, Cox-2 inhibitors are being 
increasingly used in pain management after orthopedic sur-
gery (Reuben et al. 2002). 
Both after cemented and uncemented joint replacement, a 
bone repair process starts at the bone interface because of the 
inevitable bone damage (Larsen and Ryd 1989). The extent to 
which this process is influenced by Cox inhibitors is unclear. 
If healing is disturbed, the prosthesis may never become rig-
idly fixed to the bone, leading to migration—and with time, 
loosening. An elevated number of revisions, although with 
borderline statistical significance, were found following total 
hip replacement (THR) 10 years after receiving a Cox inhibi-
tor as prophylaxis for heterotopic bone formation (Persson et 
al. 2005). Cox inhibitors are, however, effective analgesics 
and may reduce the inflammatory response to surgery; they 
have also been shown to increase the range of motion in the 
early phase of rehabilitation (Reuben et al. 2002). Thus, Cox 
inhibitors have gained wide popularity as postoperative anal-
gesics. The possible risk of impaired TKR survival has never 
been investigated, which was the reason for this study. 
Our hypothesis was that celecoxib, a selective Cox-2 inhibi-
tor, increases prosthesis migration in total knee replacement. 
Migration was measured by radiostereometric analysis (RSA), 
which constituted the primary evaluation variable. Second-
ary variables were pain, range of motion, and subjective out-
come.
Patients and methods
The study was designed as a randomized, placebo-controlled, 
double-blind  trial,  and  was  performed  in  accordance  with 
the ethical standards of the Helsinki Declaration of 1975, as 
revised in 2000. It was approved by the regional ethics commit-
tee (no. 03-286) and the Medical Product Agency in Sweden Acta Orthopaedica 2009; 80 (1): 46–50  47
(no. 151:2003/47246). The study was conducted from March 
2004 through February 2005 at the Department of Orthopedic 
Surgery, Linköping University Hospital, Sweden. 50 patients 
suffering from osteoarthritis, who met the inclusion criteria 
below, were consecutively recruited from the waiting list for 
elective primary unilateral TKR (Table 1). The inclusion cri-
teria were: age 50–80 years, ASA I–II, and capacity to give 
informed consent. The exclusion criteria were: a history of 
coagulopathy or of a thromboembolic event, plasma creatinine 
> 100 mmol/L in women and > 115 mmol/L in men, acute 
infection, malignant disease, unstable angina, myocardial or 
cerebral infarction 1 year or less before operation, and allergy 
to NSAIDs or sulfonamides. All ongoing NSAID therapy was 
discontinued 7 days before surgery and for 3 weeks postop-
eratively.
Capsules containing either placebo or celecoxib (200 mg) 
were prepared by Apoteket AB (Stockholm, Sweden). Sets of 
capsules were randomly numbered 1–50 by a computer gener-
ator in 5 blocks of 10 sets. The content of every set of capsules 
was automatically documented by computer, printed out, and 
finally stored in a sealed envelope that was numbered accord-
ing to the randomization. A research nurse administered the 
numbered sets of capsules consecutively to the patients and 
the number of each set was traced on the evaluation form for 
each patient. Thus, all 50 patients randomly received either 
placebo or celecoxib (200 mg) orally 1 h preoperatively, and 
then twice daily for 3 weeks.
All patients received NexGen prostheses (Zimmer), fixed to 
both the femur and the tibia with Palacos cum gentamicinum 
bone cement (Heraeus Medical, Germany). After partial exsan-
guination of the limb, a pneumatic tourniquet on the thigh was 
inflated to 300 mm Hg. The operation was performed by 1 of 
3 surgeons who were well experienced in this procedure. 1 
of them (AM) performed 42 of the 50 operations. Intraopera-
tively, the tibial component, an all-polyethylene construct, and 
the proximal tibia were marked with tantalum balls (diameter 
0.8 and 1.0 mm) for later radiostereometric analysis. The joint 
was drained with a single closed suction drain for 24 h postop-
eratively. Rehabilitation was initiated at the ward by a physio-
therapist and continued under supervision of physiotherapists 
for 3–8 weeks (depending on individual needs) after discharge 
from the hospital.
We recently reported the 1-year follow-up results of the 
clinical outcome variables (Meunier et al. 2007).
RSA
Index RSA radiography was conducted on the second day after 
surgery, after weight bearing had been initiated, and served as 
a baseline for subsequent measurements of migration that were 
performed after 6, 12, and 24 months. The primary evaluation 
variable was maximum total point motion (MTPM). It describes 
the vector length of the one tantalum ball in the tibial component 
with the largest range of motion without taking the direction in 
account. In addition, we report rotation and translation of the 
rigid body formed by the tantalum balls in the tibial prosthesis 
in relation to the reference body in the skeleton of the proxi-
mal tibia. Rotation about the x-axis denotes forward or back-
ward tilting of the prosthesis, rotation about the y-axis denotes 
inward or outward rotation, and rotation about the z-axis denotes 
varus-valgus tilting. Accordingly, translations along the x- and 
z-axes denote movement of the prosthesis in mediolateral and 
anteroposterior  directions,  respectively.  Translation  along  the 
y-axis denotes sinking of the prosthesis. The position of the 
tantalum ball was measured and evaluated from digitized radio-
graphs using RSA software (UmRSA; RSA Biomedical, Umeå, 
Sweden). If the mean error of the rigid body fitting exceeded 
0.35 mm, the software excluded the tantalum ball that caused the 
lack of rigidity in the rigid body, because this particular ball was 
judged not to be fixed in the rigid body any more.
The conditioning number (CN) is a gauge of measurement 
quality of the rigid body formed by the tantalum balls. The 
lower the CN, the greater is the volume of the rigid body 
formed by the balls and the better the quality of measurement. 
If the CN exceeds 90, measurement becomes inexact and that 
particular radiograph is excluded from further evaluation.
Preoperatively  and  after  3,  12  and  24  months,  pain  was 
rated with a visual analog scale (VAS) where 0 represents no 
pain and 10 represents the worst possible pain. The range of 
knee motion (ROM) was recorded by 1 of 2 physiotherapists 
preoperatively and after 3, 12, and 24 months. Subjective out-
come was assessed preoperatively and after 24 months using 
the knee injury and osteoarthritis outcome score (KOOS).
Statistics 
The primary endpoint, maximum total point motion (MTPM), 
has a minimal clinically relevant value of 0.2 mm, as sug-
gested by Ryd et al. (1995). Hence, the study was powered to 
detect a difference in MTPM of 0.2 mm between the groups. 
With a = 5% and b = 20%, and the SD for MTPM from a com-
parable study (Hilding et al. 2000), a study size of 18 patients 
per group was calculated. To compensate for possible exclu-
sion, we chose a study size of 25 patients per group.
MTPM at 24 months was analyzed using Student’s t-test. To 
avoid multiplicity-testing problems, the secondary outcome 
variables are only reported descriptively as graphs or arithme-
tic means (SD) and with the 95% confidence interval (CI) for 
group differences. In addition, for segment motion a Levene’s 
test was performed to detect significant differences in SD. Sig-
nificance was assumed at p-values less than 0.05. 
Table 1. Patient characteristics
  Placebo  Celecoxib
  (n = 25)  (n = 25)
Sex, M/F  14/11    8/17
Age, years (SD)  69 (8)  68 (6)
Time of surgery, min (SD)  87 (11)  80 (9)48  Acta Orthopaedica 2009; 80 (1): 46–50
Results
2 patients were excluded from follow-up: 1 patient in the pla-
cebo group sustained a gastric ulcer, necessitating discontinu-
ation of the study medication, and 1 patient in the celecoxib 
group had moved abroad and was not available for follow-up. 
The MTPM at 2 years was similar in both groups (celecoxib: 
0.35 mm (0.17), placebo: 0.4 mm (0.15), CI for group differ-
ence –0.15 to 0.04) (Figure 1). The calculated confidence inter-
val for the primary endpoint indicates that any real difference 
in outcome between the groups, with 95% confidence, is less 
than the pre-specified minimal clinically relevant value. No 
significant differences of rotation and translation values were 
found between the two groups (Table 2). Migration (MTPM) 
between 1 and 2 years was 0.23 mm (0.18) in the celecoxib 
group and 0.2 mm (0.07) in the placebo group (CI for group 
difference –0.5 to 0.1). There were a few more outliers in the 
celecoxib group (Figure 2). The conditioning number for the 
prosthesis segment was 21 (10) and for the reference segment 
20 (5). The mean error of rigid body fitting for the prosthesis 
segment was 0.11 (0.05) and for the reference segment 0.17 
(0.08). 
No differences were found in pain score, as measured with 
VAS. Due to skewed distribution, values had to be normalized 
by  logarithmic  transformation,  which  then  showed  similar 
means and standard deviations. In absolute values, the placebo 
group had a median value of 0.2 (interquartile range: 0–1.25) 
and the celecoxib group had a median value of 0.3 (interquar-
tile range: 0–0.95) (Figure 3).
Range of knee motion increased at the same rate in both 
groups, to the same total motion segment (flexion minus exten-
sion) (placebo: 121 degrees (SD 13); celecoxib: 123 degrees 
(SD 13); 95% CI: –10 to 6) (Figure 4).
KOOS values increased to similar extents in both groups, 
from preoperatively to 2 years after surgery (Figure 5).
Discussion
There were no differences in MTPM between the two groups, 
Figure 1. MTPM during follow-up, median (line) with interquartile range 
(boxes) and non-outliers range (whiskers),   placebo,   celecoxib,    out-
liers (values, 1,5-3-fold larger than the interquartile range), * extremes 
(values > 3-fold larger than the interquartile range).
Table 2. MTPM (mm) and segment motion (rotation in degrees and translation in mm) at 2 years
  Placebo  Celecoxib  95% CI  Levene’s test
  mean  SD  mean  SD  Min.  Max.  p-value 
 
MTPM  0.40  0.15  0.35  0.17  –0.15  0.04  0.56
Rotation x (anterior–posterior tilt)  –0.24  0.24  –0.14  0.16  –0.02  0.22  0.10
Rotation y (inward–outward rotation)  –0.01  0.18  –0.01  0.17  –0.11  0.09  0.40
Rotation z (varus-valgus tilt)  0.01  0.15  0.00  0.12  –0.09  0.06  0.43
Translation x (medial–lateral translation)  0.00  0.05  0.00  0.06  –0.02  0.04  0.17
Translation y (subsidence – lift-off)  –0.01  0.12  0.01  0.13  –0.05  0.09  0.94
Translation z (anterior–posterior translation)  0.01  0.07  0.04  0.09  –0.01  0.08  0.27
Figure 2. MTPM between 1 and 2 years.
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Figure 3. Pain during follow-up (median with interquartile range): pla-
cebo, celecoxib.
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and no differences in the rigid body motion pattern. This sug-
gests  that  celecoxib—and  thus  probably  also  other  Cox-2 
inhibitors—does not increase the risk of loosening after TKR. 
We noted a few more outliers with increased prosthesis motion 
in the celecoxib group, and these patients may be the ones with 
the highest risk of loosening (Figure 2). However, the study 
was powered to detect a difference in mean MTPM between 
the groups and not to detect a difference in the number of out-
liers. Moreover, the CI calculated is very narrow: less than 
the pre-specified minimal clinically relevant value of 0.2 mm. 
Cox inhibitors have been used for many years in pain manage-
ment after TKR, but in spite of this, the frequency of revision 
surgery due to aseptic loosening has been shown to be quite 
low—about 5% after 10 years for all revisions—according to 
the Swedish knee arthroplasty register (Harrysson et al. 2004). 
The quality of our RSA examinations was good, with low con-
ditioning numbers and low mean error of rigid body fitting. 
The magnitude of the MTPM is similar to that in comparable 
studies (Hilding et al. 2000, Norgren et al. 2004, Hyldahl et al. 
2005, Hilding and Aspenberg 2006). Other factors that could 
contribute to motion, such as positioning of the prosthesis or 
osteoporosis, were not addressed in this study, but blinding 
and randomization should have eliminated the effects of such 
factors on the result.
We found no positive effects on range of motion, pain, and 
subjective outcome (as measured with the KOOS 2 years after 
TKR) when celecoxib had been given in the early rehabilita-
tion phase. At 1 year, the results were similar (Meunier et al. 
2007). Buvanendran et al. (2003) reported better ROM and 
less pain in patients treated with a Cox-2 inhibitor after TKR. 
In our study, we could not confirm those early positive effects 
after 1 or 2 years. If there was suppression of the inflammatory 
response to the surgical trauma in the early phase of rehabili-
tation, this did not lead to improved medium-term subjective 
and objective outcome. 
In this study, we found that celecoxib given in the periop-
erative and postoperative phases of TKR did not lead to an 
increase in prosthesis migration 2 years after surgery. Cele-
coxib can safely be given as part of postoperative pain man-
agement, but there appears to be no long-term benefit regard-
ing pain, range of motion, or subjective outcome.
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